Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tharimmune ( (THAR) ) has shared an update.
On November 3, 2025, Tharimmune, Inc. announced a private placement offering expected to raise approximately $540 million, led by DRW and Liberty City Ventures. The proceeds will be used to acquire Canton Coin and support the company’s transition into blockchain technology, aiming to enhance financial infrastructure and drive institutional adoption. The offering reflects Tharimmune’s strategy to integrate blockchain technology with its existing operations, potentially impacting its market positioning and offering stakeholders a diversified value stream.
The most recent analyst rating on (THAR) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Tharimmune stock, see the THAR Stock Forecast page.
More about Tharimmune
Tharimmune, Inc. operates in the biotechnology industry with a focus on clinical-stage developments. The company is expanding its operations into the digital asset space by establishing a Canton Coin treasury strategy, leveraging blockchain technology for financial infrastructure improvements.
Average Trading Volume: 10,053,916
Technical Sentiment Signal: Buy
Current Market Cap: $22.45M
See more data about THAR stock on TipRanks’ Stock Analysis page.